Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TLX | 6-K | bullish | 7/10 | Telix reported a strong H1 2026 with revenue of $477.4M (+22% YoY), swinging to a net profit of $38.3M from a -$2.3M los | Aug 20, 2026 |
| YARW | EFFECT | bearish | 5/10 | Yarrow Bioscience's shelf registration statement (File No. 333-277609) became effective on August 19, 2026. This allows | Aug 20, 2026 |
| CUVL | 6-K | neutral | 2/10 | Clinuvel Pharmaceuticals filed a 6-K announcing that it will release its FY2026 annual results on August 27, 2026, and h | Aug 20, 2026 |
| ACIU | 6-K | bullish | 7/10 | AC Immune announced positive preliminary Phase 1 data for its wholly-owned NLRP3 inhibitor ACI-19764, showing safety, to | Aug 20, 2026 |
| NBP | 6-K | neutral | 5/10 | NovaBridge Biosciences issued an investor presentation on August 20, 2026, highlighting its clinical pipeline, financial | Aug 20, 2026 |
| NBP | 6-K | bearish | 6/10 | NovaBridge Biosciences (NBP) reported H1 2026 financial results showing a net loss of $37.9M, up from $8.7M in H1 2025, | Aug 20, 2026 |
| URGN | 8-K | neutral | 4/10 | UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics, securing an exclusive op | Aug 20, 2026 |
| CELZ | PRESS-RELEASE | neutral | 5/10 | Creative Medical Technology announced that all patients have been enrolled and treated across its ADAPT clinical trial f | Aug 20, 2026 |
| EVAX | 6-K | neutral | 4/10 | Evaxion reported Q2 2026 results in line with expectations: net loss narrowed to $3.7M (vs $4.8M YoY), cash burn continu | Aug 20, 2026 |
| BNTX | 6-K | neutral | 4/10 | BioNTech filed a 6-K press release announcing upcoming data presentations at the IASLC 2026 World Conference on Lung Can | Aug 20, 2026 |
| BFRG | 8-K | bearish | 7/10 | BullFrog AI Holdings received a second 180-day compliance period from Nasdaq, extending the deadline to February 8, 2027 | Aug 20, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K to execute a 1-for-15 reverse stock split, effective August 21, 2026, primarily to | Aug 20, 2026 |
| SLGL | 6-K | neutral | 5/10 | Sol-Gel Technologies reported Q2 2026 financial results with revenue of $0.6 million, a sharp decline from $17.3 million | Aug 20, 2026 |
| ICLR | 6-K | neutral | 2/10 | ICON plc filed its 2025 ICON Cares ESG report via a 6-K, detailing environmental, social, and governance progress. The r | Aug 20, 2026 |
| RADX | 6-K | neutral | 4/10 | Radiopharm Theranostics received a positive DSMC recommendation to advance its Phase 1 HEAT trial of 177Lu-RAD202 to Coh | Aug 20, 2026 |
| SLGL | PRESS-RELEASE | neutral | 5/10 | Sol-Gel reported Q2 2026 revenue of $0.6M (down from $17.3M a year ago, which included a $16.7M IP sale) and a net loss | Aug 20, 2026 |
| CDIO | 8-K | neutral | 2/10 | Cardio Diagnostics Holdings, Inc. filed an 8-K with an investor presentation deck. The presentation highlights its AI-po | Aug 20, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year ago, with cash of $ | Aug 20, 2026 |
| SKYE | DEFA14A | neutral | 4/10 | Skye Bioscience filed a DEFA14A to announce the effective date of its previously disclosed 1-for-8 reverse stock split, | Aug 20, 2026 |
| NBP | PRESS-RELEASE | neutral | 4/10 | NovaBridge Biosciences reported a net loss of $37.9M for H1 2026, widening from $8.7M a year ago, driven by increased R& | Aug 20, 2026 |
| RADX | PRESS-RELEASE | neutral | 4/10 | Radiopharm Theranostics announced a positive DSMC recommendation to advance its radiotherapeutic RAD202 to the next dose | Aug 20, 2026 |
| ACIU | PRESS-RELEASE | neutral | 5/10 | AC Immune announced positive preliminary Phase 1 data for its wholly-owned NLRP3 inhibitor ACI-19764, showing safety, to | Aug 20, 2026 |
| RPRX | CLUSTER | neutral | 3/10 | Two senior executives at Royalty Pharma (EVP/Chairman Hite and EVP/CFO Coyne) sold a combined $6.54M in open-market sale | Aug 20, 2026 |
| MIRM | CLUSTER | neutral | 3/10 | Two insiders at Mirum Pharmaceuticals sold a combined $4.60M in shares over a one-week window. SVP/Global Controller Jol | Aug 20, 2026 |
| ELVN | CLUSTER | neutral | 2/10 | Two C-suite insiders at Enliven Therapeutics (ELVN) sold a combined $310K in open-market sales on August 17, 2026. The C | Aug 20, 2026 |
| AVTX | CLUSTER | neutral | 3/10 | CFO Christopher Ryan and CMO Mittie executed derivative exercises and sold shares totaling ~$819K in open-market sales o | Aug 20, 2026 |
| CSTL | CLUSTER | neutral | 4/10 | Three top executives at Castle Biosciences, the CEO, CFO, and Chief Commercial Officer, sold a combined $826K in open-ma | Aug 19, 2026 |
| TAK | CLUSTER | neutral | 2/10 | Two Takeda insiders, the President of Global Supply & Quality and the Chief Human Resources Officer, sold a combined $59 | Aug 19, 2026 |
| NATR | INSIDER-BUY | bullish | 5/10 | A 10% owner, Prescott Group Capital Management, purchased $941K of NATR stock over a week, including $294K at the lowest | Aug 19, 2026 |
| INSM | CLUSTER | neutral | 4/10 | Two Insmed insiders sold a total of $32.6M in stock over the past week, including COO Roger Adsett's $31.96M sale and Di | Aug 19, 2026 |